| Thomas Lee Howe, MD | |
|
3509 22nd St, Lubbock, TX 79410-1307 | |
| (806) 799-7928 | |
| (806) 788-8500 |
| Full Name | Thomas Lee Howe |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 25 Years |
| Location | 3509 22nd St, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164425559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | L6947 (Texas) | Secondary |
| 2086S0127X | Surgery - Trauma Surgery | L6947 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lubbock Heart Hospital Lp | Lubbock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Bariatric Surgery Center | 8527085034 | 2 |
News Archive
Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction.
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.
Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.
Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).
› Verified 2 days ago
| Entity Name | Advanced Bariatric Surgery Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063588804 PECOS PAC ID: 8527085034 Enrollment ID: O20051024001070 |
News Archive
Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction.
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.
Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.
Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).
› Verified 2 days ago
| Entity Name | Texas Tech University Health Sciences Center Lubbock |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063461358 PECOS PAC ID: 4385549674 Enrollment ID: O20110318000468 |
News Archive
Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction.
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.
Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.
Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Lee Howe, MD 3506 21st St, Ste 610, Lubbock, TX 79410-1212 Ph: (806) 799-7928 | Thomas Lee Howe, MD 3509 22nd St, Lubbock, TX 79410-1307 Ph: (806) 799-7928 |
News Archive
Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction.
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.
Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.
Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).
› Verified 2 days ago
Ted W Allen, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8560 | |
Sammy Anthony Deeb, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3509 22nd St, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8500 | |
Monja L Proctor, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4102 22nd Pl, Lubbock, TX 79410 Phone: 806-725-0237 Fax: 806-725-1030 | |
Dr. Brittany Kay Bankhead, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-2373 Fax: 806-743-4354 | |
Adam Purtell, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8560 | |
Dr. Gerald Lynn Woolam, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-771-2222 Fax: 806-771-2224 | |
Delphine Engel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-2370 Fax: 806-743-1475 |